Published in J Clin Oncol on June 01, 1999
Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients (DECENDO) | NCT04212377
Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev (2013) 1.91
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol (2011) 1.80
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol (2011) 1.58
Role of progesterone in endometrial cancer. Semin Reprod Med (2010) 1.53
Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab (2011) 1.46
The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology (2007) 1.14
Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proc Natl Acad Sci U S A (2010) 1.13
EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer (2009) 1.13
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer (2016) 1.06
Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist (2015) 1.05
Wnt/Β-catenin and sex hormone signaling in endometrial homeostasis and cancer. Oncotarget (2010) 1.01
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol (2014) 0.98
Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstet Gynecol Int (2010) 0.97
Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev (2010) 0.97
The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast Cancer Res (2005) 0.94
Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy. Cancer Res (2013) 0.90
The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology (2008) 0.89
Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update (2014) 0.87
Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer. Oncotarget (2014) 0.87
Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. PLoS One (2012) 0.87
Epigenetic modification restores functional PR expression in endometrial cancer cells. Curr Pharm Des (2014) 0.86
Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health (2014) 0.86
Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus. Int J Dev Biol (2014) 0.86
Progress in gynecologic cancer research: the Gynecologic Oncology Group experience. Semin Oncol (2008) 0.85
Treatment for advanced and recurrent endometrial carcinoma: combined modalities. Oncologist (2010) 0.84
Involvement of cyclin B1 in progesterone-mediated cell growth inhibition, G2/M cell cycle arrest, and apoptosis in human endometrial cell. Reprod Biol Endocrinol (2009) 0.83
Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma. Oncol Hematol Rev (2013) 0.82
Long-term survival of patients with recurrent endometrial stromal sarcoma: a multicenter, observational study. J Gynecol Oncol (2015) 0.82
Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma. Oncol Lett (2012) 0.81
Influence of AKT on progesterone action in endometrial diseases. Biol Reprod (2014) 0.80
Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. Oncotarget (2013) 0.80
Endometrial adenocarcinoma in a 27-year-old woman. Clin Med Insights Case Rep (2010) 0.80
Comparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer. Eur J Gynaecol Oncol (2012) 0.78
Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells. Oncogene (2016) 0.78
Preservation of ovarian function during chemotherapy and radiotherapy in young women with malignancies. Iran J Reprod Med (2014) 0.78
Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. Oncologist (2016) 0.77
A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol (2015) 0.76
EMT-Inducing Molecular Factors in Gynecological Cancers. Biomed Res Int (2015) 0.76
Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. J Gynecol Oncol (2016) 0.76
Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: a case report and review of the literature. Arch Oncol (2010) 0.76
Breast cancer in the setting of fertility-sparing treatment for endometrial cancer. Gynecol Oncol Rep (2014) 0.75
Extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 overexpression is associated with loss of hormone receptor expression and poor prognosis in endometrial cancer. Oncol Lett (2015) 0.75
Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition. Int J Gynecol Cancer (2017) 0.75
Molecular targeted therapy in gynaecologic malignancies: primer for radiologists. Br J Radiol (2016) 0.75
Progesterone potentiates the growth inhibitory effects of calcitriol in endometrial cancer via suppression of CYP24A1. Oncotarget (2016) 0.75
Overexpression of progesterone receptor A isoform in mice leads to endometrial hyperproliferation, hyperplasia and atypia. Mol Hum Reprod (2009) 0.75
Fourth-Generation Progestins Inhibit 3β-Hydroxysteroid Dehydrogenase Type 2 and Modulate the Biosynthesis of Endogenous Steroids. PLoS One (2016) 0.75
Nucleophosmin/B23 is a negative regulator of estrogen receptor α expression via AP2γ in endometrial cancer cells. Oncotarget (2016) 0.75
Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus. Surg Pathol Clin (2012) 0.75
Challenging Regimen for Long-Term Conservative Treatment of Endometrial Adenocarcinoma in Young Women: A Case Report and Review of the Literature. Case Rep Oncol (2010) 0.75
Association of body mass index with ER, PR and 14-3-3σ expression in tumor and stroma of type I and type II endometrial carcinoma. Oncotarget (2017) 0.75
Norethindrone substituted for megestrol in the treatment of metastatic endometrial carcinoma: Three cases. Gynecol Oncol Rep (2017) 0.75
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer (1987) 5.36
Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol (1991) 4.62
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol (2000) 4.48
Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med (1990) 2.97
Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer (1993) 2.96
Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res (1990) 2.55
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol (1994) 2.50
Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res (1986) 2.37
A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol (2000) 2.34
Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol (1995) 2.17
Primary vaginal melanoma: improved survival with radical pelvic surgery. Gynecol Oncol (1994) 2.14
Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol (1991) 2.13
Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res (1986) 2.01
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol (1996) 1.91
Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst (1993) 1.71
Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol (2001) 1.70
Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol (1994) 1.69
A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol (1989) 1.67
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol (1998) 1.67
Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol (1996) 1.66
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst (1993) 1.60
p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol (1996) 1.59
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol (1990) 1.59
Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma. Gynecol Oncol (1994) 1.56
Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer (2007) 1.53
Comparison of adenocarcinoma and squamous cell carcinoma of the uterine cervix: a population-based epidemiologic study. Am J Obstet Gynecol (1992) 1.51
What is a normal CA125 level? Gynecol Oncol (1994) 1.48
Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol (1993) 1.47
Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol (1995) 1.47
A phase II trial of neoadjuvant chemotherapy prior to radical hysterectomy and/or radiation therapy in the management of advanced carcinoma of the uterine cervix. Gynecol Oncol (1995) 1.44
A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol (1993) 1.44
Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon. Gynecol Oncol (1992) 1.42
Structural and functional integrity of ovarian tumor tissue obtained by ultrasonic aspiration. Cancer (1991) 1.40
A prospective evaluation of transvaginal sonography for detection of ovarian disease. AJR Am J Roentgenol (1993) 1.39
Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect Immun (1998) 1.36
Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol (1986) 1.34
Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol (1991) 1.31
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol (1996) 1.31
Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol (1999) 1.28
Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol (1995) 1.27
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27
The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol (2000) 1.27
Malignant germ cell tumors of the ovary. Obstet Gynecol (2000) 1.25
A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer (1986) 1.25
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (1995) 1.23
Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. Int J Gynecol Pathol (1992) 1.19
Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy. Obstet Gynecol (1992) 1.19
Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol (1995) 1.15
Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol (1990) 1.13
The MIT D-lab electricity-free PortaTherm™ incubator for remote testing with the QuantiFERON®-TB Gold In-Tube assay. Int J Tuberc Lung Dis (2010) 1.11
Rectovaginal fistula. A review of 20 years' experience in a community hospital. Am J Obstet Gynecol (1970) 1.11
Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res (1992) 1.11
An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther (2001) 1.10
Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther (2005) 1.10
Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol (2001) 1.09
Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol (1998) 1.09
Relationship between race and interval to treatment in endometrial cancer. Obstet Gynecol (1995) 1.08
Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol (1991) 1.07
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol (2001) 1.07
Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol (2001) 1.06
Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol (2001) 1.06
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med (1996) 1.05
Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol Oncol (1995) 1.04
Recruitment strategies for cervical cancer prevention study. Gynecol Oncol (2002) 1.04
Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer (1993) 1.04
Hazards of central venous pressure monitoring: pericardial tamponade. Am J Obstet Gynecol (1971) 1.04
Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer (1983) 1.04
An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol (1996) 1.03
Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol (1992) 1.02
Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol (1998) 1.02
Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. Gynecol Oncol (1990) 1.02
Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. Cancer Res (1989) 1.02
Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol (1992) 1.02
Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol (1999) 1.02
A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol (1994) 1.01
High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol (1996) 1.00
Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter. Gene Ther (2004) 1.00
Frictional properties of Hartley guinea pig knees with and without proteolytic disruption of the articular surfaces. Osteoarthritis Cartilage (2006) 1.00
Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. Hum Gene Ther (2000) 0.99
Ureteroarterial fistulae in exenteration patients with indwelling ureteral stents. Gynecol Oncol (1993) 0.99
Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res (2001) 0.98
Binding of specific peroxidase-labeled antibody to placental-type phosphatase on tumor-derived membrane fragments. Cancer Res (1980) 0.97
Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol (1995) 0.97
"Membrane-associated" immunoglobulins in cyst and ascites fluids of ovarian cancer patients. Am J Reprod Immunol (1983) 0.97
Prognostic factors in patients with advanced stage prostate cancer. Cancer Res (1985) 0.96
Viral latency--the papillomavirus model. Dev Biol (Basel) (2001) 0.96
Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther (2009) 0.95
Placental-type alkaline phosphatase in ovarian cancer fluids and tissues. Obstet Gynecol (1984) 0.95
CA125 as a serum marker for poor prognosis in ovarian malignancies. Gynecol Oncol (1987) 0.95